이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

2026년 11월 12일 업데이트: Merck Sharp & Dohme LLC

1B/2 개방형-라벨, 다기관 연구는 고급 세로 상피 난소, 1 차 복구 또는 나팔 튜브 암을 가진 참가자의 유무에 관계없이 Raludotatug deruxtecan의 안전성 및 효능을 평가하기위한 1B/2 개방형, 다기관 연구.

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.

Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:

  • Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
  • Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread

Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.

연구 유형

중재적

등록 (추정된)

605

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Taipei, 대만, 100225
        • 모병
        • National Taiwan University Hospital ( Site 3001)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +886223123456
      • Taoyuan, 대만, 33305
        • 모병
        • Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +88633281200
      • Seoul, 대한민국, 03080
        • 모병
        • Seoul National University Hospital ( Site 2000)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82220723511
      • Seoul, 대한민국, 03722
        • 모병
        • Severance Hospital, Yonsei University Health System ( Site 2002)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82222282230
      • Seoul, 대한민국, 05505
        • 모병
        • Asan Medical Center ( Site 2003)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82230103646
      • Seoul, 대한민국, 06351
        • 모병
        • Samsung Medical Center ( Site 2001)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 82234101382
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, 대한민국, 10408
        • 모병
        • National Cancer Center ( Site 2004)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 82319201760
    • Connecticut
      • New Haven, Connecticut, 미국, 06510
        • 모병
        • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 203-785-2404
    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • 모병
        • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 502-562-3429
    • Louisiana
      • Shreveport, Louisiana, 미국, 71103
        • 모병
        • TRIALS 365 ( Site 0020)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 318-408-1198
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Dana-Farber Cancer Institute ( Site 0015)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 877-338-7425
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center ( Site 0003)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 212-639-2000
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • OU Health University of Oklahoma Medical Center ( Site 7000)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 405-271-1112
    • Texas
      • Fort Worth, Texas, 미국, 76104
        • 모병
        • Texas Oncology - DFW ( Site 8000)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 615-329-7430
      • Houston, Texas, 미국, 77030
        • 완전한
        • Houston Methodist Hospital ( Site 0010)
    • Utah
      • West Valley City, Utah, 미국, 84119
        • 모병
        • START Mountain Region ( Site 0008)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 801-907-4750
    • Virginia
      • Charlottesville, Virginia, 미국, 22908
        • 모병
        • University of Virginia Health System ( Site 0011)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 434-924-9333
      • Sankt Gallen, 스위스, 9000
        • 모병
        • HOCH Health Ostschweiz ( Site 0801)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +41714941111
    • Canton of Basel-City
      • Basel, Canton of Basel-City, 스위스, 4031
        • 모병
        • University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +41613284214
    • Canton of Vaud
      • Lausanne, Canton of Vaud, 스위스, 1011
        • 모병
        • CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +41795567362
      • Barcelona, 스페인, 08035
        • 모병
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +349325434528607
      • Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre ( Site 0304)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34913908626
      • Madrid, 스페인, 28040
        • 모병
        • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 34915504800 x2805
      • Málaga, 스페인, 29010
        • 모병
        • Hospital Universitario Virgen de la Victoria ( Site 0306)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34951032508
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 08908
        • 모병
        • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34932607744
    • Madrid
      • Majadhonda, Madrid, 스페인, 28222
        • 모병
        • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34 911917358
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, 스페인, 28027
        • 모병
        • Clinica Universidad de Navarra ( Site 0301)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +349135319207513
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, 스페인, 46014
        • 모병
        • Hospital General Universitario de Valencia ( Site 0305)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34 963187527
      • Manchester, 영국, M20 4BX
        • 모병
        • The Christie NHS Foundation Trust ( Site 0405)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +441619187689
    • East Sussex
      • Brighton, East Sussex, 영국, BN2 1ES
        • 모병
        • University Hospitals Sussex NHS Foundation Trust ( Site 0404)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +44 01273 696 955
    • England
      • Fulham, England, 영국, SW3 6JJ
        • 모병
        • Royal Marsden Hospital ( Site 0402)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +442078118084
      • Sutton, England, 영국, SM2 5PT
        • 모병
        • The Royal Marsden NHS Foundation Trust. ( Site 0403)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +442078118084
    • London, City of
      • London, London, City of, 영국, E1 1RD
        • 모병
        • Barts Health NHS Trust ( Site 0401)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 020 7377 7000
      • London, London, City of, 영국, SE1 3SS
        • 모병
        • Guy s & St Thomas NHS Foundation Trust ( Site 0400)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +44 020 7188 7188
      • Haifa, 이스라엘, 3109601
        • 모병
        • Rambam Health Care Campus ( Site 0202)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 972-4-7776234
      • Jerusalem, 이스라엘, 9103102
        • 모병
        • Shaare Zedek Medical Center ( Site 0201)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +972-(0)2-6555424
      • Petah Tikva, 이스라엘, 4941492
        • 모병
        • Rabin Medical Center ( Site 0203)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97239378076
      • Ramat Gan, 이스라엘, 5265601
        • 모병
        • Sheba Medical Center ( Site 0200)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 972-3-5304498
    • Ontario
      • Toronto, Ontario, 캐나다, M5G 2M9
        • 모병
        • Princess Margaret Cancer Centre ( Site 0101)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 416-946-2818
    • Quebec
      • Montreal, Quebec, 캐나다, H4A 3J1
        • 모병
        • McGill University Health Centre ( Site 0100)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 514-934-1934x31975
      • Montreal, Quebec, 캐나다, H2X 0A9
        • 모병
        • Centre Hospitalier de l'Université de Montréal ( Site 0102)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 514-890-8000
    • Victoria
      • St Albans, Victoria, 호주, 3021
        • 모병
        • Western Health-Sunshine & Footscray Hospitals ( Site 1002)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +61402775432

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
  • Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
  • Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
  • Has provided tumor tissue for biomarker research (all cohorts)
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 1
  • Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
  • Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant

Exclusion Criteria:

  • Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
  • Has uncontrolled or significant cardiovascular disease
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
  • Has ≥Grade 2 peripheral neuropathy
  • Has received prior treatment with cadherin-6-targeted agents
  • Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
  • Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Receives chronic steroid treatment
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active CNS metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
  • Has active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)

Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

실험적: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)

Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

실험적: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)

Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

실험적: Cohort B-1 (R-DXd + Bevacizumab)

Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • 소싱에 따라 다음이 포함됩니다.
  • - 아바스틴®
  • - Alymsys®
  • - 엠바시®
  • - 오야바스®
  • - 지라베브®
  • - 베그젤마®
  • - Aybintio®
  • - 브레즈트리®
실험적: Cohort B-2 (R-DXd RP2D + Bevacizumab)

Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • 소싱에 따라 다음이 포함됩니다.
  • - 아바스틴®
  • - Alymsys®
  • - 엠바시®
  • - 오야바스®
  • - 지라베브®
  • - 베그젤마®
  • - Aybintio®
  • - 브레즈트리®
실험적: Cohort C-1 (R-DXd + Pembrolizumab)

Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

실험적: Cohort D (R-DXd +/- Bevacizumab)

Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • 소싱에 따라 다음이 포함됩니다.
  • - 아바스틴®
  • - Alymsys®
  • - 엠바시®
  • - 오야바스®
  • - 지라베브®
  • - 베그젤마®
  • - Aybintio®
  • - 브레즈트리®
실험적: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • 소싱에 따라 다음이 포함됩니다.
  • - 아바스틴®
  • - Alymsys®
  • - 엠바시®
  • - 오야바스®
  • - 지라베브®
  • - 베그젤마®
  • - Aybintio®
  • - 브레즈트리®
실험적: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • 소싱에 따라 다음이 포함됩니다.
  • - 아바스틴®
  • - Alymsys®
  • - 엠바시®
  • - 오야바스®
  • - 지라베브®
  • - 베그젤마®
  • - Aybintio®
  • - 브레즈트리®
활성 비교기: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)

Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • 소싱에 따라 다음이 포함됩니다.
  • - 아바스틴®
  • - Alymsys®
  • - 엠바시®
  • - 오야바스®
  • - 지라베브®
  • - 베그젤마®
  • - Aybintio®
  • - 브레즈트리®

IV injection on days 1 and 8 of each 3-week Cycle

IV injection administered on Day 1 of each 4-week cycle

다른 이름들:
  • PLD
실험적: Cohort E-1 (R-DXd + MK-2010)

Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle

실험적: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)

Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles).

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

실험적: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)

Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

실험적: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)

Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease.

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle.

다른 이름들:
  • 소싱에 따라 다음이 포함됩니다.
  • - 아바스틴®
  • - Alymsys®
  • - 엠바시®
  • - 오야바스®
  • - 지라베브®
  • - 베그젤마®
  • - Aybintio®
  • - 브레즈트리®

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
기간: Up to 21 days

DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
기간: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.

Up to approximately 3 years
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
기간: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Objective Response Rate (ORR)
기간: Up to approximately 3 years

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
기간: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years

2차 결과 측정

결과 측정
측정값 설명
기간
Part 1: Objective Response Rate (ORR)
기간: Up to approximately 3 years

ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR).

Up to approximately 3 years
Part 2: Duration of Response (DOR)
기간: Up to approximately 3 years

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
기간: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years
Part 2: Overall Survival (OS)
기간: Up to approximately 5 years

OS is defined as the time from the first dose of study treatment to death due to any cause.

Up to approximately 5 years
Part 2: Number of Participants with One or More AEs
기간: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
기간: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 15일

기본 완료 (추정된)

2029년 3월 27일

연구 완료 (추정된)

2031년 2월 7일

연구 등록 날짜

최초 제출

2025년 2월 20일

QC 기준을 충족하는 최초 제출

2025년 2월 20일

처음 게시됨 (실제)

2025년 2월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 5909-003
  • MK-5909-003 (기타 식별자: MSD)
  • U1111-1308-2821 (레지스트리 식별자: UTN)
  • 2024-514674-47-00 (레지스트리 식별자: EU CT)
  • REJOICE-Ovarian02 (기타 식별자: MSD)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .